Potent Acid Suppression: The Role of Vonoprazan in Pediatric GERD

Emerging research highlights the clinical efficacy of vonoprazan in pediatric GERD, providing a potential shift from standard proton pump inhibitor therapies. Vonoprazan, a potassium-competitive acid blocker (P-CAB), offers faster and more sustained gastric pH elevation compared to traditional options. Specifically, this latest study evaluated the pharmacokinetics and safety of vonoprazan in forty-two children and adolescents aged 6 to 17 years who suffer from symptomatic gastroesophageal reflux disease.

Moreover, the research team randomized subjects to receive either 10 mg or 20 mg of the drug once daily for 14 days. Consequently, researchers utilized a robust two-compartment population model, originally developed for adults, to compare pediatric drug concentrations. Notably, the model analyzed the area under the concentration-time curve (AUC) and the individual oral clearance rates across the cohort.

Pharmacokinetics of Vonoprazan in Pediatric GERD

The model-based analyses revealed that drug exposures in pediatric subjects were nearly identical to those observed in adult patients. Furthermore, both the 10 mg and 20 mg dose levels yielded pharmacokinetic parameters that mirrored noncompartmental estimates from previous adult studies. Similarly, children and adolescents reported a noticeable improvement in their GERD symptoms, regardless of whether they received the lower or higher dosage.

In addition, the safety profile of the medication was favorable throughout the duration of the study. Notably, while subjects reported six treatment-emergent adverse events, only one was considered related to the study drug. Importantly, no serious adverse events occurred, and no participants discontinued the treatment due to side effects. Therefore, these findings confirm that the 10 mg and 20 mg vonoprazan doses are appropriate and well-tolerated for managing acid reflux in the pediatric population.

Frequently Asked Questions

How does vonoprazan differ from standard PPIs for children?

Vonoprazan acts as a potassium-competitive acid blocker (P-CAB). Unlike traditional PPIs, it does not require an empty stomach for activation and provides more rapid, durable acid suppression. This study suggests these benefits translate effectively to pediatric patients with safety profiles similar to adults.

Are the 10 mg and 20 mg doses safe for adolescents?

Yes, the clinical data indicates that both 10 mg and 20 mg doses are well-tolerated in adolescents. The study found that drug exposure levels in this age group are nearly identical to those in adults, with minimal drug-related side effects reported.

Does vonoprazan improve actual GERD symptoms in children?

Participants in the clinical study reported qualitative improvements in GERD symptoms and their severity across both dosage groups, suggesting that the drug is effective for symptomatic relief in children aged 6 to 17 years.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Mulford DJ et al. The pharmacokinetics and safety of vonoprazan in adolescents and children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2026 Feb 21. doi: 10.1002/jpn3.70368. PMID: 41721637.

Laine L et al. Vonoprazan is efficacious for treatment of heartburn in non-erosive reflux disease: a randomized trial. Clin Gastroenterol Hepatol. 2024;22:2211.

Chey WD et al. Vonoprazan for the Treatment of Erosive Esophagitis and Nonerosive Reflux Disease. Clin Gastroenterol Hepatol. 2023.